HC Wainwright & Co. Maintains Buy on PDS Biotechnology, Raises Price Target to $15
Benzinga Newsdesk 11 months ago
NewsPrice TargetAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $13 to $15.
HC Wainwright & Co. analyst Joseph Pantginis maintains PDS Biotechnology (NASDAQ:PDSB) with a Buy and raises the price target from $13 to $15.